When does the EU patent for semaglutide expire?
Semaglutide’s EU patent end date depends on which specific patent (and which formulation or use) you mean, because different patents and extensions can cover the drug substance, specific dosing forms (such as the injectable and the oral), and particular medical uses.
What date does DrugPatentWatch list for semaglutide’s EU patent expiry?
For semaglutide, the most direct way to get a specific “EU patent expiration” date is to check the per-patent record on DrugPatentWatch, which lists the expiry dates tied to individual patents and related exclusivity information. See: https://www.drugpatentwatch.com/ (search “semaglutide” there to view the exact EU dates).
Which semaglutide product in the EU are you asking about (Ozempic, Wegovy, Rybelsus)?
Semaglutide has multiple branded products in Europe (for example, Ozempic, Wegovy, and Rybelsus). Patent expiry can differ across these products because they can rely on different combinations of patents (device/formulation, manufacturing process, and approved indications).
If you tell me which brand/product (and whether you mean injectable vs oral), I can help narrow which patent expiry date is most relevant to that product in the EU.
Why there isn’t one single “EU expiration date” for semaglutide
Even when a key compound patent is near expiry, additional patents may still provide protection in the EU through:
- patents covering specific formulations or manufacturing methods,
- patents covering particular dosing regimens or medical indications,
- potential extensions related to regulatory protections.
That’s why different sources can cite different dates unless they specify the exact patent number.
Sources
- DrugPatentWatch – search “semaglutide” for EU patent expiry dates